Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RIZATRIPTAN BENZOATE vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Acute treatment of migraine with or without aura in adults.,Acute treatment of migraine with or without aura in pediatric patients 6 to 17 years of age.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
2-3 hours in adults; clinically, no significant accumulation with multiple dosing.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Primarily metabolized by monoamine oxidase A (MAO-A) via oxidative deamination; minor metabolism by aldehyde oxidase. The major metabolite is the inactive N-desmethyl rizatriptan.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Primarily hepatic metabolism via monoamine oxidase-A, with ~14% excreted unchanged in urine; total recovery of radioactivity in urine is ~82% (30% unchanged drug, 52% metabolites) and ~9% in feces over 24 hours.
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
14%
92-98% bound primarily to albumin.
140 L (approximately 2 L/kg in adults), indicating extensive tissue distribution.
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral: ~45% (due to first-pass metabolism); intranasal: ~42% (compared to subcutaneous sumatriptan); orally disintegrating tablet: ~45%.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
No dosage adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Not recommended in patients with severe hepatic impairment (Child-Pugh class C) due to absence of studies. For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; use caution.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Children 6-17 years: 5-10 mg orally at onset; may repeat after 2 hours; maximum 30 mg per 24 hours. Weight <40 kg: start 5 mg. Weight ≥40 kg: may use 10 mg.
Safety and efficacy not established; use is not recommended in pediatric patients.
Elderly patients may have increased risk of adverse effects. Start at 5 mg; use caution with comorbidities and concomitant medications. No specific dose adjustment required; monitor cardiovascular status.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None
No FDA black box warning.
Risk of myocardial ischemia and/or infarction, coronary artery vasospasm, cerebrovascular events, and increased blood pressure. Serotonin syndrome (especially when co-administered with other serotonergic drugs). Use only after clear diagnosis of migraine; not for use in hemiplegic or basilar migraine. Caution in patients with risk factors for coronary artery disease. Avoid use within 24 hours of other 5-HT1 agonists or ergotamine derivatives. Monitor for signs/symptoms of serotonin syndrome.
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
History of ischemic heart disease (angina, myocardial infarction, silent ischemia), coronary artery vasospasm (Prinzmetal's angina), or other significant cardiovascular disease. Uncontrolled hypertension. Hemiplegic or basilar migraine. Use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. Concurrent use or within 2 weeks of monoamine oxidase inhibitor (MAOI) therapy. Known hypersensitivity to rizatriptan or any component. Severe hepatic impairment (Child-Pugh class C).
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
No significant food interactions. However, high-fat meals may delay absorption. Avoid alcohol as it may worsen headaches or increase side effects.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats or rabbits but was associated with embryo-fetal toxicity at maternotoxic doses. Use only if potential benefit justifies potential risk to the fetus. First trimester: no specific data, but theoretical risk of vasoconstriction. Second and third trimesters: may cause uterine contractions or reduced uterine blood flow.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Rizatriptan is excreted in human milk at very low levels; the milk-to-plasma ratio is approximately 0.07. The estimated infant dose is about 3% of the maternal weight-adjusted dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for rizatriptan and potential adverse effects on the breastfed infant.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume, altered metabolism) may reduce exposure. Use lowest effective dose for shortest duration. If migraine severity warrants, standard dosing (5-10 mg oral, may repeat after 2 hours, max 30 mg/24h) may be used.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
Rizatriptan is a selective 5-HT1B/1D receptor agonist used for acute migraine. Onset of action is rapid (30 min). Maximum daily dose is 30 mg (oral tablets) or 30 mg (ODT). Do not use within 24 hours of other triptans or ergotamines. Contraindicated in patients with ischemic heart disease, uncontrolled hypertension, or basilar/hemiplegic migraine. Avoid in patients with moderate/severe hepatic impairment. ODT dissolves quickly and can be taken without water, useful for patients with nausea.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Take at the first sign of migraine headache; it will not prevent attacks.,Do not exceed 30 mg in any 24-hour period (separate doses by at least 2 hours).,If first dose does not work, do not take a second dose for the same attack without consulting your doctor.,Seek emergency care if you experience chest pain, shortness of breath, or sudden severe headache.,Inform your doctor if you have heart disease, high blood pressure, or are taking MAOIs (within 2 weeks) or other migraine medications.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
"Co-administration of rizatriptan, a selective 5-HT1B/1D receptor agonist, with sertraline, a selective serotonin reuptake inhibitor (SSRI), increases the risk of serotonin syndrome due to additive serotonergic effects. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients should be monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, especially during initiation or dose escalation."
"Paroxetine, a selective serotonin reuptake inhibitor (SSRI), inhibits the metabolism of rizatriptan, a triptan used for migraine, via CYP1A2 and possibly other pathways, leading to increased rizatriptan plasma concentrations. This elevates the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular abnormalities, autonomic instability, and altered mental status. Clinically, patients may experience symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, requiring prompt recognition and management."
"The combination of rizatriptan, a serotonin 5-HT1B/1D receptor agonist, and ziprasidone, an atypical antipsychotic with serotonergic activity (5-HT2A antagonist and weak serotonin reuptake inhibition), may increase the risk of serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This additive serotonergic effect occurs through overlapping mechanisms, including enhanced 5-HT1A and 5-HT2A receptor activation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RIZATRIPTAN BENZOATE vs ADALAT CC, answered by our medical review team.
RIZATRIPTAN BENZOATE is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RIZATRIPTAN BENZOATE and ADALAT CC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RIZATRIPTAN BENZOATE is: 5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RIZATRIPTAN BENZOATE and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RIZATRIPTAN BENZOATE is classified as Category D/X. Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats o. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.